Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes

Oncology
Mustafa BenekliSuleyman Buyukberber

Abstract

Treatment of patients with metastatic breast cancer (MBC) exposed to anthracyclines and taxanes is challenging. Effective and well-tolerated regimens are required. Gemcitabine plus capecitabine combination was assessed in MBC patients pretreated with anthracyclines and taxanes. A total of 31 patients treated between November 2004 and September 2005 were retrospectively evaluated in 4 institutions. The median age was 48 years (range 29-77). The patients were given gemcitabine 1,000 mg/m(2) on days 1 and 8, and capecitabine 1,500 mg/m(2) twice daily on days 1-14 every 3 weeks. A total of 160 cycles of chemotherapy were administered with a median of 5 cycles per patient (range 2-12). Three patients achieved a partial response (10%) and 8 patients (26%) stable disease. The median time to disease progression was 6 months (95% CI 5-7), with a median survival of 18 months (95% CI 15-21) at a median follow-up of 16 months (range 2-28). One-year and 2-year survival rates were 67 and 28%, respectively. Grade 3-4 toxicities were as follows: neutropenia (n = 11, 35%), nausea and vomiting (n = 4, 13%), hand-foot syndrome (n = 2, 6%), anemia (n = 2, 6%), thrombocytopenia (n = 2, 6%) and asthenia (n = 1, 3%). The combination of gemcitabine pl...Continue Reading

References

Nov 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J CarmichaelA L Harris
Oct 1, 1998·The New England Journal of Medicine·G N Hortobagyi
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MiwaH Ishitsuka
Mar 20, 2002·Clinical Breast Cancer·C H SmorenburgJ Verweij
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L ZelekM Spielmann
Feb 3, 2004·Clinical Breast Cancer·Shanu Modi, Andrew D Seidman
Feb 14, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P FumoleauM Namer
Feb 18, 2004·The Breast : Official Journal of the European Society of Mastology·T BrodowiczC C Zielinski
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy D MillerHope S Rugo
Dec 22, 2005·The Oncologist·Joyce O'Shaughnessy
Feb 14, 2006·Seminars in Oncology·Ian Smith
Feb 1, 2006·Seminars in Oncology·Ian Smith

❮ Previous
Next ❯

Citations

Nov 27, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E M CiruelosJ Baselga

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.